{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T16:53:24Z","timestamp":1780332804407,"version":"3.54.1"},"reference-count":29,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Neurourology and Urodynamics"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Guidelines recommend initial cystometrography in patients with supra\u2010sacral spinal cord injuries. Contemporary data on cohort composition and related adherence to neurogenic bladder guidelines is limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess treads in cohort composition and the proportion of persons with spinal cord injury who were seen by a urologist and who underwent cystometrography.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We identified the cohort of veterans with supra\u2010sacral spinal cord injury in whom neurogenic bladder guidelines may apply. Measures included whether the veteran was seen by a urologist and had a cystometrography procedure performed within 2 years of the first SCI\/D clinic or hospital encounter. We also examined trends over 20+ year cohort composition and overall survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cohort consisted of 49\u2009347 veterans with a mean follow\u2010up of 10.2 (SD 6.5) years. The number of new patients was more than 3000 in 2000 and has been approximately 1200 from 2020 to 2023. Prevalent patients peaked in 2019 at 25\u2009812, followed by a decline. Eighty percent of veterans had at least one record of lower urinary tract symptoms within 1 year of their first SCI\/D encounter, and more than 55% received medication for urinary conditions or urinary supplies. An urologist visit was reported for 14\u2009408 (29%) veterans, and cystometrography (CMG) was performed in 15\u2009512 (31%) veterans. Over 20+ years, from 2000 to 2023, the mean age of new patients increased by almost 9 years, as did the proportion of veterans with baseline comorbidities; for example, the proportion of veterans with diabetes increased from 17% in 2000 to more than 45% in 2022. Median survival was 13.3 (IQR: 6.4\u201322.4).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The characteristics of veterans with supra\u2010sacral SCI\/D have changed to older age and more comorbidities, and most veterans have recorded lower urinary tract symptoms early after the initial SCI\/D encounter. Given the study's insights into changing patient demographics, the crucial role of CMG, and the low rates of specialized urological care, there is a pressing need for enhanced awareness, surveillance, and updated treatment strategies tailored for this unique patient population. This paper calls for a concerted effort to improve healthcare delivery for veterans with supra\u2010sacral SCI\/D, aiming for early diagnosis and treatment to optimize outcomes and quality of life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration Statement<\/jats:title>\n                    <jats:p>\n                      The study does not require clinicaltrials. gov trial registration. The reason is that is we did not \u201cprospectively assign people or a group of people to an intervention\u201d (ICMJE, Section I.1). Supplemental materials for the fourth paper in this series includes a STROBE statement (STrengthening the Reporting of OBservational studies in Epidemiology;\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/www.strobe-statement.org\">https:\/\/www.strobe-statement.org<\/jats:ext-link>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/nau.70259","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T11:31:07Z","timestamp":1773055867000},"page":"705-712","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["In\u2010Depth Real\u2010World Evidence: Assembling a Comprehensive Spinal Cord Injury or Disease Veteran Cohort to Advance Understanding of Neurogenic Lower Urinary Tract Dysfunction"],"prefix":"10.1002","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9888-2205","authenticated-orcid":false,"given":"John","family":"Hornberger","sequence":"first","affiliation":[{"name":"Department of Veterans Affairs Palo Alto Health Care System Urology Section Palo Alto California USA"},{"name":"Departments of Internal Medicine and Urology Stanford University Stanford California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8202-0835","authenticated-orcid":false,"given":"John","family":"Lavelle","sequence":"additional","affiliation":[{"name":"Department of Veterans Affairs Palo Alto Health Care System Urology Section Palo Alto California USA"},{"name":"Departments of Internal Medicine and Urology Stanford University Stanford California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00287-9"},{"key":"e_1_2_12_3_1","unstructured":"\u201cUrinary Incontinence in Neurological Disease Management of Lower Urinary Tract Dysfunction in Neurological Disease: NICE Clinical Guidelines. Royal College of Physicians (UK) \u201dNational Clinical Guideline Centre (UK) 2012 accessed September 23 2024 https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK132831\/?report=reader."},{"key":"e_1_2_12_4_1","unstructured":"VHA Directive 1176(2): Spinal Cord Injuries and Disorders System of Care. U.S. Department of Veterans Affairs; 2019 accessed June 24 2025 https:\/\/www.va.gov\/vhapublications\/ViewPublication.asp?pub_ID=8523."},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.03.026"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000002235"},{"issue":"5","key":"e_1_2_12_7_1","first-page":"527","article-title":"Bladder Management for Adults With Spinal Cord Injury: A Clinical Practice Guideline for Health\u2010Care Providers","volume":"29","author":"Consortium for Spinal Cord Medicine","year":"2006","journal-title":"Journal of Spinal Cord Medicine"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.5912"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2015.01.060"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2015.06.005"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003021"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.23369"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1310\/sci2301-78"},{"key":"e_1_2_12_14_1","unstructured":"U.S. Department of Veterans Affairs. VA Health Systems Research: Corporate Data Warehouse (CDW) accessed June 23 2025 https:\/\/www.hsrd.research.va.gov\/for_researchers\/cdw.cfm."},{"key":"e_1_2_12_15_1","volume-title":"VIReC Corporate Data Warehouse (CDW) Domain Descriptions","author":"Culbreath C.","year":"2019"},{"key":"e_1_2_12_16_1","unstructured":"SAS Institute Inc. SAS\u00ae Enterprise Guide\u00ae 8.3 [Computer Software] User Guide. Published online 2020."},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.23163"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2005.02.009"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ucl.2010.06.002"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/10790268.2018.1512729"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.20319"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/sc.2014.205"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.23599"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67013-9"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11247307"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1179\/2045772314Y.0000000208"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.sc.3100638"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5347(17)58506-7"},{"key":"e_1_2_12_29_1","unstructured":"US Food and Drug Administration. CBER Biologics Effectiveness and Safety (BEST) System.2024 https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/cber-biologics-effectiveness-and-safety-best-system."},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13886"}],"container-title":["Neurourology and Urodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/nau.70259","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/nau.70259","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/nau.70259","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T03:20:05Z","timestamp":1778815205000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/nau.70259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1002\/nau.70259"],"URL":"https:\/\/doi.org\/10.1002\/nau.70259","archive":["Portico"],"relation":{},"ISSN":["0733-2467","1520-6777"],"issn-type":[{"value":"0733-2467","type":"print"},{"value":"1520-6777","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"assertion":[{"value":"2025-01-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}